Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Equivalents (2016 - 2021)

Historic Cash & Equivalents for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $311.1 million.

  • Neurocrine Biosciences' Cash & Equivalents fell 2685.16% to $311.1 million in Q3 2021 from the same period last year, while for Sep 2021 it was $311.1 million, marking a year-over-year decrease of 2685.16%. This contributed to the annual value of $190.3 million for FY2020, which is 6945.68% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Cash & Equivalents of $311.1 million as of Q3 2021, which was down 2685.16% from $368.0 million recorded in Q2 2021.
  • Neurocrine Biosciences' Cash & Equivalents' 5-year high stood at $425.3 million during Q3 2020, with a 5-year trough of $64.1 million in Q1 2017.
  • Over the past 5 years, Neurocrine Biosciences' median Cash & Equivalents value was $190.3 million (recorded in 2020), while the average stood at $227.2 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Cash & Equivalents soared by 25885.49% in 2017, and later tumbled by 5848.63% in 2019.
  • Neurocrine Biosciences' Cash & Equivalents (Quarter) stood at $254.7 million in 2017, then crashed by 44.36% to $141.7 million in 2018, then dropped by 20.76% to $112.3 million in 2019, then surged by 69.46% to $190.3 million in 2020, then soared by 63.48% to $311.1 million in 2021.
  • Its last three reported values are $311.1 million in Q3 2021, $368.0 million for Q2 2021, and $352.6 million during Q1 2021.